Trial
NCT04965272
A Study To Assess Adverse Events and Change in Disease Activity With Oral Cariprazine When Added to Antidepressant Therapies (ADTs) Compared to Placebo in Adult Participants With Generalized Anxiety Disorder (GAD) Who Have Had an Inadequate Response to ADTs Alone
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
AbbVie
Collaborators
—
Condition
Generalized Anxiety Disorder
Intervention
Cariprazine 0.75 mg/day
Why stopped
Strategic Decision
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-04-12